News By Tag
News By Location
Cancer-Code Corporation Announces Licensing of Revolutionary Cancer Treatment Technology
ALBUQUERQUE, NM - Cancer Code Corporation (C3) announces that it is the licensee of the cancer treatment approach covered in four pending patent applications based on inventor Eleanor Schuler’s neuro-code technology.
The U.S. patent applications are as follows:
U.S. Patent Application Serial No. 12/334,212 entitled “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.
U.S. Patent Application Serial No. 12/936,778 entitled “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.
U.S. Patent Application Serial No. 12/812,576 entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”
U.S. Patent Application Serial No. 12/936,791 entitled “Hybrid Scientific Computer System for Processing Cancer Cell Signals as Medical Therapy”
This cancer killing technology has the potential to replace current chemotherapy approaches, and represents the dawn of an entirely new treatment approach using tiny encoded signals to destroy cancer, quickly. This new and exciting breakthrough is based on the fact that all cells communicate, including cancer cells. This approach will “signal” the cancer cells to kill themselves.
About Cancer-Code Corporation
C3, located in Albuquerque, NM, is focusing on the development and testing of cancer treatment technology that takes advantage of the fact that all cells have an electrical process and adjacent cells communicate with one another. The approach of C3 is geared toward this cancer cell communication and “wrecking"
Additional information about Cancer-Code Corporation can be found at http://www.cancercodecorp.com
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Donald E. Nash, President
Cancer Code Corporation
117 Bryn Mawr Dr S.E.
Albuquerque, NM 87106